Introduction
Professor Wang Biyun (王碧詠) is a Professor of Medical Oncology at Fudan University Shanghai Cancer Center (FUSCC) — one of China's most prestigious and highest-volume cancer centers. Professor Wang is recognized as one of Shanghai's leading breast cancer medical oncologists, with particular expertise in HER2-positive breast cancer, triple-negative breast cancer (TNBC), and advanced metastatic breast cancer management. Working alongside Chief Professor Hu Xichun in one of China's most respected breast cancer medical oncology programs, Professor Wang has established herself as a leading expert in breast cancer systemic treatment. Her expertise spans the full spectrum of breast cancer medical oncology, with particular distinction in antibody-drug conjugates (ADCs), immunotherapy for TNBC, and novel targeted agents for metastatic breast cancer. International patients with breast cancer consistently regard Professor Wang as a premier choice at FUSCC.
Academic Distinctions & Leadership
- Professor of Medical Oncology, Fudan University Shanghai Cancer Center (FUSCC)
- Member, Chinese Society of Clinical Oncology (CSCO)
- Breast Cancer Committee Member, CSCO
- Member, Chinese Anti-Cancer Association, Breast Cancer Committee
- Editorial Board Member, multiple Chinese oncology journals
- Recipient, multiple Shanghai municipal and national science and technology awards
- Visiting fellow at leading breast cancer centers internationally
Specializations & Expertise
HER2-Positive Breast Cancer
- Pertuzumab + trastuzumab + chemotherapy (TCHP) neoadjuvant therapy
- T-DM1 for residual HER2+ disease after neoadjuvant therapy
- T-DXd (trastuzumab deruxtecan) for metastatic HER2+ breast cancer
- Tucatinib + trastuzumab + capecitabine for metastatic HER2+ breast cancer
- Lapatinib-based regimens for brain metastases
- Neratinib extended adjuvant therapy
- HER2-low breast cancer management with T-DXd
Triple-Negative Breast Cancer (TNBC)
- Neoadjuvant chemotherapy + immunotherapy (pembrolizumab) for TNBC
- Sacituzumab govitecan (Trodelvy) for metastatic TNBC
- PARP inhibitors (olaparib, talazoparib) for BRCA-mutated TNBC
- Capecitabine adjuvant therapy for residual TNBC
- Immunotherapy for PD-L1 positive metastatic TNBC
- Androgen receptor-positive TNBC management
Hormone Receptor-Positive Breast Cancer
- CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib)
- Endocrine therapy optimization
- PI3K inhibitors (alpelisib) for PIK3CA-mutated HR+ breast cancer
- AKT inhibitors (capivasertib) for AKT-pathway altered breast cancer
- ESR1 mutation management (elacestrant)
Antibody-Drug Conjugates (ADCs)
- T-DXd (trastuzumab deruxtecan) for HER2+ and HER2-low breast cancer
- Sacituzumab govitecan for TNBC
- Datopotamab deruxtecan for HR+ breast cancer
- ADC toxicity management (ILD, cytopenias)
Clinical Excellence & Innovation
- ADC Expert: One of Shanghai's most experienced oncologists in antibody-drug conjugate therapy for breast cancer, with extensive experience managing ADC-related toxicities including ILD
- TNBC Immunotherapy: Expert in immunotherapy combinations for TNBC including pembrolizumab + chemotherapy and management of immune-related adverse events
- HER2-Low Breast Cancer: Pioneer in the emerging field of HER2-low breast cancer treatment with T-DXd
- Clinical Trial Access: Active participation in clinical trials of novel breast cancer agents at FUSCC
- Metastatic Breast Cancer: Comprehensive management of metastatic breast cancer including brain metastases and visceral crisis
Research & Academic Contributions
Professor Wang is an active researcher with peer-reviewed publications in leading Chinese and international oncology journals. Her research focuses on HER2-positive breast cancer treatment, TNBC immunotherapy, ADC therapy, and novel targeted agents for metastatic breast cancer.
Hospital Affiliation
Fudan University Shanghai Cancer Center (FUSCC)
270 Dongan Road, Xuhui District, Shanghai 200032
FUSCC is one of China's most prestigious cancer centers, featuring:
- One of China's highest-volume breast cancer programs
- Comprehensive breast cancer MDT
- Advanced molecular profiling (NGS, HER2, PD-L1, BRCA)
- Clinical trial access for novel breast cancer agents
- International patient services with English-speaking coordinators
Why Choose Professor Wang Biyun?
- ADC Therapy Expert: Extensive experience with T-DXd, sacituzumab govitecan, and ADC toxicity management
- HER2-Low Pioneer: Expert in this emerging breast cancer subtype
- TNBC Immunotherapy: Comprehensive TNBC immunotherapy expertise
- Clinical Trial Access: Novel agent access through FUSCC clinical trials
- Cost-Effective Excellence: Breast cancer treatment costs in Shanghai are typically 60-80% lower than in the US or Europe
- Proven International Track Record: Trusted by patients from around the world
Conditions Treated
- HER2-positive breast cancer (early and metastatic)
- HER2-low breast cancer
- Triple-negative breast cancer (early and metastatic)
- BRCA-mutated breast cancer
- Hormone receptor-positive breast cancer
- Breast cancer with brain metastases
- Inflammatory breast cancer
International Patient Services
China Medical Concierge - Shanghai (CMCS) provides comprehensive support for international patients seeking breast cancer medical oncology care with Professor Wang Biyun at FUSCC.
Pre-Arrival Support
- Medical Record Review: Review of your pathology, HER2/ER/PR/BRCA status, NGS, staging CT/PET, and prior treatment history
- Virtual Consultation: Video consultation with Professor Wang's team
- MDT Review: Arrangement of multidisciplinary breast cancer team review
- Treatment Planning: Personalized systemic treatment plan
- Cost Transparency: Detailed cost estimate
- Visa Assistance: Medical visa guidance and invitation letters
- Travel Arrangements: Flights, airport pickup, and accommodation near the hospital
During Treatment
- Professional Medical Interpretation: Experienced oncology interpreters at all appointments
- Hospital Navigation Support: Registration, payment, and hospital navigation assistance
- Infusion Support: Accompaniment during chemotherapy and ADC infusions
- 24/7 Support: Round-the-clock assistance for any concerns
Post-Treatment Care
- Report Translation: Complete translation of all pathology and treatment reports
- Treatment Summary: Comprehensive oncology summary for your home oncologist
- Medication Guide: Detailed oral medication and targeted therapy instructions
- Telemedicine Follow-up: Virtual follow-up with Professor Wang's team
- Long-term Support: Ongoing assistance after returning home
Schedule Your Consultation
If you or a loved one has breast cancer and is seeking expert medical oncology care including the latest ADC therapies and immunotherapy, Professor Wang Biyun at Fudan University Shanghai Cancer Center offers world-class expertise at a fraction of Western costs.
Contact China Medical Concierge - Shanghai today to request a pathology and staging review, schedule a virtual consultation, and begin planning your journey to Shanghai for expert breast cancer care.
Bridging international patients with Shanghai's finest breast cancer oncologists — because your breast cancer care deserves the latest in precision oncology.
0 commentaire